Revance Therapeutics
Developing neuromodulators for the treatment of aesthetic and therapeutic conditions. Learn more
Launch date
Employees
Market cap
€621m
Enterprise valuation
€857m (Public information from Sep 2024)
Share price
$5.85 RVNC
Nashville Tennessee (HQ)
Authorizing premium user...